Last updated 9 months ago
Feasibility Study of the Tioga TMVR System
30 patients around the world
Available in Brazil
The Tioga TMVR Feasibility Study is a prospective, single-arm, multi-center study with a planned enrollment of up to 30 patients. The Tioga TMVR System is designed to percutaneously replace a patient's diseased native mitral valve with a bioprosthetic valve. The investigational device is intended for transseptal replacement of the mitral valve in patients with symptomatic MR (MR>=3+).
Tioga Cardiovascular, Inc.
1Research sites
30Patients around the world
This study is for people with
Cardiovascular Disease
Mitral Regurgitation
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Age 18 years or older.Symptomatic, moderate to severe (3+) or severe (4+) MR.NYHA Functional Classification ≥ II.Heart team concurs that the subject is non-ideal for surgical intervention or other available treatment options (e.g., TEER).The subject or the subject's legal representative has been informed of the nature of the study, has agreed to return for post-procedure follow-up visits, and has provided informed consent.
- LVEF < 30%.LVEDD > 70 mm.Anatomic features (e.g., annular dimensions, neo-LVOT area, transfemoral and transseptal access, MAC) unsuitable for the Tioga TMVR System.Severe aortic valve stenosis or regurgitation.Severe right ventricular dysfunction or severe tricuspid valve disease.Evidence of intracardiac thrombus, vegetation, or mass.Prior mitral valve intervention.Prior prosthetic heart valve in any position.Any percutaneous coronary, carotid, or other endovascular intervention within 30 days prior to enrollment.Any carotid surgery within 30 days prior to enrollment.Any open cardiac or vascular surgery (other than carotid surgery) within 90 days prior to enrolment.Myocardial infarction within 30 days prior to enrollment.Cardiac resynchronization therapy (CRT) device implanted within 30 days of enrollment.History of endocarditis within 6 months prior to enrollment or evidence of active systemic infection or sepsis.Planned cardiovascular procedure within 30 days of enrolment.Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 30 days of enrollment.Active peptic ulcer or active GI bleeding within 90 days of enrollment.Cardiogenic shock or hemodynamic instability requiring inotropic support or mechanical heart assistance.Pulmonary arterial hypertension with fixed PASP > 70mmHg or PVR > 5WU that cannot be reduced to less than 5WU with vasodilator therapy.Severe chronic obstructive pulmonary Disease (COPD) or airways disease requiring continuous home oxygen.Renal insufficiency (eGFR <20 mL/min) or ESRD on dialysis.Life expectancy < 12 months.Subject is on the waiting list for a transplant or has had a prior heart transplant.Child class C cirrhosis.Blood dycrasias as defined by acute anemia with Hb < 9, platelets < 75K, WBC < 0.5.Female subjects who is breast feeding or pregnant or planning to become pregnant within the study period.Known hypersensitivity or contraindication to procedural, post procedural medication (e.g., contrast solution) or hypersensitivity to nickel or titanium.Inability to tolerate anticoagulation or antiplatelet therapies.
Sites
InCor - Instituto do Coração do HCFMUSP
Recruiting
SponsorTioga Cardiovascular, Inc.
Study typeInterventional
Conditions
Mitral Regurgitation
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06038838
